Breast Cancer Coverage from Every Angle

Melinda L. Telli, MD, on Talazoparib as Monotherapy for BRCA Mutation–Positive, HER2-Negative Breast Cancer

Posted: Wednesday, July 14, 2021

Melinda L. Telli, MD, of Stanford University, discusses the clinical implications of phase II findings that suggest talazoparib provides pathologic complete response rates comparable to those observed with combination anthracycline and taxane-based chemotherapy regimen for patients with HER2-negative, germline BRCA1/2 mutation–positive breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.